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OBJECTIVE: To optimize the design of a large, complex, pro-
posed trial, and to estimate the power / precision / sample-size /
effect-size relationships of that trial, by means of a realistic
Monte-Carlo simulation. The proposed trial would evaluate the
third-party-payer cost-effectiveness of using standardized com-
bination regimen kits vs. current practice to manage and treat
acute sinusitis. Availability of standardized kits could potentially
simplify non-prescription product selection, improve adherence,
and prevent unnecessary antibiotic prescribing. METHODS:
Using the R programming language, we simulated all essential
operational features of the proposed trial—presentation of
patients with bacterial or viral sinusitis, randomization to usual
care or one of two standardized kits; effectiveness of the ﬁrst-
round regimen, and prescription (if necessary) of second-round
therapy. Using best available literature values for bacterial and
viral sinusitis prevalence, distribution of prescription and OTC
medication costs, and response rates to various regimens, and
using various postulated sample sizes and kit costs, 1000 simu-
lations of each scenario were run. Cost-effectiveness, power, pre-
cision, and sensitivity analyses were conducted on the simulated
outcomes. RESULTS: Empirical models of power as a function
of effect size, sample-size, response rates, and kit costs were ﬁtted
to the simulation results; these were used to create interactive
graphical displays showing the power-vs.-sample-size curves, and
precision-of-cost-estimate curves, for any response rate and kit
cost. The ease of manipulation of these graphs permitted the
rapid exploration of many alternative scenarios, leading to an
optimized study design. CONCLUSIONS: The simulation analy-
sis of this complex trial permitted not only the reliable estima-
tion of power and precision for a complex study, but also
provided a framework for thinking rigorously and quantitatively
about the design of the study, and for acquiring and utilizing
available data required for the optimization of the study.
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OBJECTIVES: To measure the costs of delivering inactivated
inﬂuenza vaccinations to adults in non-traditional settings. Non-
traditional settings may represent an opportunity for boosting
inﬂuenza immunization coverage rates for recommended adults.
METHODS: We collected data through telephone surveys with
representatives of organizations that conduct mass vaccination
clinics for inﬂuenza vaccination in a variety of non-traditional
settings, such as employer sites, retail stores and pharmacies (n
= 7) and pharmacies that use pharmacists to deliver vaccinations
(n = 5). Telephone interviews were conducted between January
and April, 2004. Data on costs of vaccine dose, supplies, cli-
nical and administrative labor costs, overhead, promotion/
advertising, number of vaccinations delivered, and waiting and
vaccination time for vaccine recipients were collected. Time costs
were calculated using 2003 average US wage data. Primary out-
comes were total costs per vaccination delivered including and
excluding recipient time costs. RESULTS: Survey participants
delivered 4.5 million doses of inﬂuenza vaccine through mass
vaccination clinics and 300,000 doses via pharmacists for the
2003–2004 inﬂuenza season. Mean total costs per vaccination,
not including time costs, were estimated to be $17.04 (95% CI:
$14.43–$19.66) for mass vaccination clinics and $11.57 (95%
CI: 9.79–$13.35) for pharmacists. If time costs were included,
total vaccination costs were $20.52 (95%CI: $17.38–23.66) for
mass vaccination clinics and $15.20 (95%CI: $12.21–18.20) for
pharmacists. The largest single component of costs was the cost
of the vaccine dose (range = $6.75–$8.95). Mean waiting and
vaccination times for the recipient were estimated to be 12
minutes in both settings. CONCLUSIONS: Compared to pub-
lished estimates of delivering inﬂuenza vaccination through
scheduled visits in the traditional physician ofﬁce setting of
$21.34–$50.43 (Coleman MS et al., 2005), costs of delivering
inﬂuenza vaccination may be lower in non-traditional settings.
Data on costs of vaccination by speciﬁc setting type are required
for evaluating the cost-effectiveness of delivering inﬂuenza vac-
cination in non-traditional versus traditional settings.
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OBJECTIVES: We evaluated the long-term clinical beneﬁts and
costs associated with HAART from a societal perspective with
respect to its current efﬁcacy, and explored the cost-effectiveness
of therapies of greater efﬁcacy. METHODS: A Monte Carlo
Markov model was created to simulate the treatment sequence
and disease progression and costs for a hypothetical cohort 
of 10,000 asymptomatic, treatment-naïve patients initiating
HAART with CD4 cell count of 200–350 cells/mL and viral load
of 100–55,000 RNA copies/mL. The model’s treatment states are
two distinct HAART regimens, a rescue regimen, and no antivi-
ral treatment. During each yearly cycle, the patient has either
therapeutic success or failure with no AIDS-related infections,
AIDS, AIDS-related death, or death from other causes, the prob-
abilities of which (except other cause death) are dependent on
CD4 cell count. Model parameters were derived from published
literature and data from the Multicenter AIDS Cohort Study.
Assuming future treatment strategies improve upon the utility of
HAART by increasing the probability of treatment success by at
least 10%, we estimate mean costs and quality adjusted life years
(QALYs) of HAART and future treatments. RESULTS: Mean
costs of non-HAART (modeled for comparison), HAART and
rescue regimens are $7739, $14,468, and $34,196, respectively.
Mean costs of AIDS and AIDS-related death are $28,772 and
$67,533, respectively. Mean survival times are 5.19 and 2.55
years (4.01 and 1.92 QALYs) for the HAART and non-HAART
cohorts, respectively. Mean discounted (at 3%) lifetime cost of
HAART was $171,313. The ICER of HAART over non-HAART
was $22,570/QALY. Future treatment strategies of 10% greater
efﬁcacy lead to a mean of 0.43 QALYs gained at a cost of $5749
($13,318/QALY). Future treatment costs <120% of current
HAART, have an ICER of <$0,000/QALY. CONCLUSIONS:
Even modest increases in treatment success and cost result in
additional QALYs well below the generally accepted threshold.
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IS RELIEF WORTH THE RISK? RISK-BENEFIT PREFERENCES
FOR TREATMENTS FOR VASOMOTOR SYMPTOMS
Johnson FR, Hauber AB, Ozdemir S
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OBJECTIVES: To derive valid estimates of women’s willingness
to accept elevated fracture, cardio-vascular and cancer risks in
return for the beneﬁts of treatments that reduce vasomotor
symptoms. METHODS: This study used a pretested stated-
